Nephrology & urology
Kidney & urinary clinical trials
Kidney disease and conditions of the bladder and urinary tract. We’re tracking 4,504 recruiting studies in this area right now.
By phase
- Not applicable2,821
- Phase 2564
- Phase 1366
- Phase 3271
- Phase 1/Phase 2230
- Phase 4194
- Phase 2/Phase 358
Top conditions
- Prostate Cancer651
- Bladder Cancer191
- Acute Kidney Injury136
- Chronic Kidney Diseases131
- Breast Cancer104
- Chronic Kidney Disease104
- Renal Cell Carcinoma80
- Urinary Incontinence64
- Colorectal Cancer60
- Kidney Cancer60
- Ovarian Cancer60
- Lung Cancer55
- Lupus Nephritis54
- Cancer51
- Melanoma50
- Benign Prostatic Hyperplasia48
- Prostate Cancer (Adenocarcinoma)46
- Renal Cancer46
Leading sponsors
- Mayo Clinic62
- National Cancer Institute (NCI)45
- Peking University First Hospital38
- M.D. Anderson Cancer Center36
- Novartis Pharmaceuticals35
- Chinese University of Hong Kong34
- AstraZeneca30
- Memorial Sloan Kettering Cancer Center29
- Assistance Publique - Hôpitaux de Paris28
- University of California, San Francisco28
Where studies are running
- California350
- Alabama112
- Arizona103
- Florida97
- New York95
- Maryland91
- Texas91
- Massachusetts88
- Illinois66
- Ohio48
Recruiting studies4,504 total
- NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT03102554Enrolling by invitation
Study genes in sex development differences and hypospadias
This study looks for genetic causes of differences in how a baby or child’s sex organs develop, including hypospadias. You may be able to join if doctors can’t find a reason using standard testing.
Boston, MassachusettsAges Any age - NCT06678828Enrolling by invitation
Testing a new blood test for prostate cancer risk
This study is testing a new blood test, ClarityDX Prostate, to see if it can help doctors better decide who needs a biopsy. It is for men who have been referred to a urologist because there is a suspicion of prostate cancer but who have not been diagnosed yet.
Calgary, AlbertaAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Birmingham, AlabamaAges 18 years+ - NCT07614152RecruitingPhase 3
Growth hormone treatment for girls with Turner syndrome
This study tests whether a new long-acting growth hormone injection helps girls with Turner syndrome grow taller. Turner syndrome is a genetic condition that affects growth, and this trial will see if this treatment is safe and effective.
AnyangAges 2–12 - NCT06274047RecruitingPhase 3
Hormone Therapy Timing for Prostate Cancer After Surgery
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
Gilbert, ArizonaAges 18 years+ - NCT06168487RecruitingPhase 1
Telmisartan for stable prostate cancer
This trial tests the blood pressure medication telmisartan in men with prostate cancer who are already on a stable treatment and not needing an immediate change. The goal is to see if adding telmisartan can help control the cancer without extra side effects.
Lebanon, New HampshireAges 18 years+ - NCT03549754Recruiting
iCaReMe registry for adults with diabetes, blood pressure, or heart/kidney disease
This is a health “registry,” meaning it collects information about people living with common chronic conditions. It may help researchers better understand real-world health needs and outcomes for people with type 2 diabetes, high blood pressure, heart failure, and/or chronic kidney disease.
Fortaleza, CearáAges 18 years+ - NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80 - NCT07582133RecruitingPhase 2
Long-term safety study of HRS-5965 for IgA kidney disease
This study follows up on patients who participated in a previous trial (HRS-5965-305) testing a drug called HRS-5965 for IgA nephropathy, a kidney disease where the immune system damages the kidneys. Researchers want to check if the drug continues to be safe and well-tolerated over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Birmingham, AlabamaAges 18 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Gilbert, ArizonaAges 18 years+ - NCT07717242RecruitingPhase 2
Bladder cancer study testing a new drug combination before surgery
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Guangzhou, GuangdongAges 18 years+ - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT07302451RecruitingPhase 2
Recovering erectile function after prostate cancer treatment
This trial tests a program to help men recover erectile function after prostate cancer treatment. It is for men with a specific type of prostate cancer that hasn't spread and who still have some erectile function.
NaplesAges 18 years+ - NCT04798690Recruiting
Long-term growth injections for short children
This trial studies the long-term safety and effectiveness of Growtropin®-II, a growth hormone–type injection, in children who are short due to certain causes. It may help your child’s growth over time, while also closely tracking side effects.
Seoul, Seodaemun-guAges 2 years+ - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07307456RecruitingPhase 2
Toripalimab and BCG for high-risk bladder cancer
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07543757Recruiting
Blood test to help decide if prostate biopsy is needed
This study tests whether a new blood test called Proclarix can better predict which men actually have prostate cancer before they undergo a biopsy. If the test works well, it could help avoid unnecessary biopsies in the future.
Meridian, IdahoAges 40–75 - NCT06094543Recruiting
Improving access and adherence for overactive bladder treatment
This study compares two ways to help women with overactive bladder get treatment and stick with it. You might be able to join if you are a woman with ongoing OAB symptoms and haven't had certain treatments recently.
Redwood City, CaliforniaAges 18 years+ - NCT07707232Recruiting
Using AI to read PSMA PET/CT reports for prostate cancer
This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.
Wenzhou, ZhejiangAges 18 years+
Common questions
- How many kidney & urinary clinical trials are recruiting?
- Clin2 is tracking 4,504 recruiting nephrology & urology studies from the U.S. registry right now, out of 7,162 we cover in this area in total.
- What does “Kidney & urinary” cover here?
- Kidney disease and conditions of the bladder and urinary tract. We group each study into kidney & urinary based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a kidney & urinary trial near me?
- Use the search to filter kidney & urinary studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.